Target intelligence / Profile preview

Forty-two-three domain containing 1 pseudogene

Molecular classification
Other
01

Overview

"Forty-two-three domain containing 1 pseudogene" is a noncoding genomic sequence homologous to the protein-coding gene FYTTD1 (also known as UIF, UAP56-interacting factor)[2][4]. Pseudogenes typically arise from gene duplication or retrotransposition events and are generally nonfunctional due to disabling mutations. While most pseudogenes like this do not encode proteins, some may exert regulatory effects at the RNA level, impacting gene expression or acting as competing endogenous RNAs, though no such functionality is established for this pseudogene[3]. The parent gene, FYTTD1, is involved in mRNA export from the nucleus[7], but the pseudogene itself does not retain this function. There are no known drug interactions, therapeutic mechanisms, or established biomarker roles for this pseudogene. - The use of "forty-two-three domain containing 1 pseudogene" as a target is likely incorrect for therapeutic or research targeting purposes, as it is not an active receptor, enzyme, transporter, or signaling protein. - If a functional target is intended, the correct target should be "Forty-two-three domain containing 1" (FYTTD1, UIF), not the pseudogene variant[2][4][7].

Other names
Forty-two-three domain-containing protein 1 pseudogeneUIF pseudogeneFYTTD1 pseudogene
02

Biological functions

Other
03

Disease associations

Other

Beyond the preview

Go deeper on Forty-two-three domain containing 1 pseudogene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forty-two-three domain containing 1 pseudogene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call